NPC delegate calls for national negotiations on prices of imported consumables

Zhou Haibou, National People's Congress delegate and president of Guangdong Qingyuan People's Hospital, submitted a motion during the "Two Sessions" meeting of the National People's Congress and the Chinese People's Political Consultative Conference proposing that steps be taken to bring down unreasonably high prices of high-value medical consumables.

Zhou underlined the high prices of some imported high-value consumables relative to peer markets, particularly Taiwan (see table). For example, artificial hip joints are available in Guangdong at twice the price point of Taiwan, while coronary artery stents are 1.5 times more expensive. Zhou underlined that high prices for consumables are passed on to patients.

Solutions to the problem, in Zhou's view, should include establishing provincial-level medical consumables centralized procurement platforms, fully implementing "two-invoice" system reforms to the distribution of consumables; and medical institutions should be permitted to carry out grouped procurement and secondary price negotiations, with hospitals permitted to retain any disparities between prices on the provincial platform and actual procurement price. Imported high-value products such as artificial joints, heart stents, and other high-value consumables with windfall profits should undergo nationally managed price negotiations, in Zhou's view.



Price in Taiwan

Price in Guangdong


Cementless ceramic hip prosthesis

NTD 96,360 (RMB 21,413)

RMB 40,000


Bone cement, ceramic hip prosthesis

NTD 96,513 (RMB 21,447)

RMB 38,000


Coronary artery coated stent

NTD 71,099 (RMB 15,799)

RMB 21,000


Sustained coronary stent

NTD 71,099 (RMB 15,799)

RMB 21,000


Related news
Xiamen, one of the 11 cities included in the "4+7" national centralized drug procurement pilot scheme, is moving to initiate drug procurement according to the "4+7" prices negotiated in December, according to a notice from the medical security bureau.
Chongqing Healthcare Security Administration (CHSA) released a notification relating to "4+7" national centralized drug procurement pilot scheme winning bids pricing, indicating that, the winning bid prices will be adopted as of March 20, 2019, in the province-level municipality. The government-owned public hospitals within the administrative division will have to sell the 25 winning bids at the winning prices as of March 20, according to the document.
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform released a notification on the national centralized drug procurement pilot scheme, or "4+7" project.
China's State Medical Insurance Agency (SMIA) released an Opinions paper “On the National Centralized Drug Procurement Pilot Scheme and Matching Medical Insurance Measures”.
Quanyaowang, the entity responsible for the public hospital group procurement organization (GPO) in Shenzhen, released a draft proposal relating to the “4+7” drug procurement pilot scheme, geared towards the city itself.
Recent news
Alfonso Ramírez Cuéllar, president of the Budget Commission in Mexico’s House of Representatives, urged the Ministry of Finance and Public Credit (SHCP) to disclose the names of 10 pharmaceutical companies that have received contracts for 80% of the consolidated drug purchases during previous administrations.
Colombia’s National Food and Drug Surveillance Institute (INVIMA) last month approved Switzerland-based Roche’s hemophilia drug Hemlibra (emicizumab), as GBI analysis found.
France-based Sanofi-Aventis saw its diabetes drug Soliqua (insulin glargine + lixisenatide) obtain registration from Colombia’s National Food and Drug Surveillance Institute (INVIMA), according to GBI analysis.
According to GBI analysis, Ecuador’s National Agency for Health Regulation, Control and Surveillance (ARCSA) last month granted registration to Switzerland-based Ferring’s oral anti-inflammatory Cortiment (budesonide).
Switzerland-based giant Novartis AG has officially launched its Ultibro (indacaterol glycopyrronium bromide, powder for inhalation, hard capsules) and Seebri (glycopyrronium bromide, powder for inhalation, hard capsules) chronic obstructive pulmonary disease (COPD) maintenance therapies into the Chinese market.
  • 1552880244053
  • China
  • Drug
Sino-U.S. biotech Xynomic Pharma announced the receipt of clinical trial approvals in China, Spain, and Poland for its histone deacetylase (HDAC) inhibitor abexinostat in combination with pazopanib for patients with renal cell carcinoma (RCC).
  • 1552879902162
  • China
  • Drug
China-based vaccines specialist CanSino Biotechnology Inc., is moving to hold an initial public offering (IPO) of 5,725,200 H shares to the Hong Kong Stock Exchange (HKSE) Main Board from March 28, 2019 alongside another 51,523,400 H shares to the global market, with the price range currently at HKD 21 to HKD 22 per share.
Analytics Snapshot

Actionable intelligence at your fingertips.